Inflammation inhibiting compounds
The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of αMSH for inducing tolerance.
1. A method for treatment of psoriasis comprising the step of administering to a patient in need of such treatment, a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of Lys-(D)Pro-Thr [K(D)PT] (KPT), N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound, wherein said therapeutically effective amount is in the range from 20 μg/kg of body weight to 10 mg/kg of body weight.
2. The method according to claim 1 , wherein said pharmaceutical composition is in the form of an ointment or cream.
3. The method according to claim 2 , wherein said compound is present in the ointment or cream in a concentration of 1 μM to 1 mM.
4. The method according to claim 1 , wherein said pharmaceutical composition is formulated for intraperitoneal, intravenous or oral administration.
5. The method according to claim 1 , wherein said pharmaceutical composition further comprises at least one additional compound selected from the group consisting of Lys-Pro, N-acyl Lys-Pro, C-amide Lys-Pro, C-esters of Lys-Pro, Lys-(D)Pro-Thr [K(D)PT] (KPT), N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr.
6. A method for treatment of psoriasis comprising the step of administering to a patient in need of such treatment, an ointment for topical application, said ointment containing a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound, wherein said compound is present in said ointment in a concentration of from 1 μM to 1mM.